Cost effectiveness of the new pneumococcal vaccines: A systematic review of European studies

PharmacoEconomics

Volumn 32, Issue 1, 2014, Pages 29-45

  Van De Vooren, Katelijne ^a   Duranti, Silvy ^a   Curto, Alessandro ^a   Garattini, Livio ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PCV 7; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG MARKETING; ECONOMIC EVALUATION; EUROPEAN UNION; HERD IMMUNITY; HUMAN; PHARMACOECONOMICS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; VACCINATION;

COSTS AND COST ANALYSIS; EUROPE; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 84896297134     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0113-y     Document Type: Review

References (141)

1. Immunization, vaccine and biologicals. Pneumococcal disease. World Health Organization. 2011. http://www.who.int/immunization/topics/pneumococcal- disease/en/. Accessed 17 June 2013.
2. Immunization, vaccine and biologicals. Pneumococcal vaccines. World Health Organization. 2003. http://www.who.int/vaccines/en/pneumococcus. shtml#vaccines. Accessed 17 June 2013.
3. Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination - a review (2002-2006). Vaccine. 2007;25(8):1355-67. (Pubitemid 46074293)
4. Boonacker CW, Broos PH, Sanders EA, et al. Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review. Pharmacoeconomics. 2011;29(3):199-211.
5. Farkouh RA, Klok RM, Postma MJ, et al. Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions. Expert Rev Vaccines. 2012;11(10):1235-47.
6. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes. A focused review of modelling approaches. Pharmacoeconomics. 2008;26(3):191-215. (Pubitemid 351271379)
7. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013;1:CD000422.
8. Tocheva AS, Jefferies JM, Rubery H, et al. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children. Vaccine. 2011;29(26):4400-4.
9. European Centre for Disease Prevention and Control. Surveillance of invasive pneumococcal disease in Europe, 2010. Stockholm: ECDC; 2012.
10. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19(3):187-95. (Pubitemid 30167436)
11. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21(9):810-5.
12. Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22(1):10-6. (Pubitemid 36091771)
13. Eskola J, Kilpi T, Palmu A, Finnish Otitis Media Study Group, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344(6):403-9. (Pubitemid 32128672)
14. Prymula R, Peeters P, Chrobak V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumonia and non-typable Haemophilus influenza: a randomised double blind efficacy study. Lancet. 2006;367(9512):740-8. (Pubitemid 43326292)
15. Cozza V, Kanitz E, D'Ancona F, et al. Impact of childhood pneumococcal vaccination programmes and activities for pneumococcal vaccines in the EU and EEA\EFTA countries.Report VENICE II. 2012. http://venice.cineca.org/VENICE- Survey-PNC-1-2012-02-24.pdf.
16. De Pouvourville G, Ulmann P. Nixon et al. The diffusion of health economics knowledge in Europe. The EURONHEED (European Network of Health Economic Evaluation Databases) Project. Pharmacoeconomics. 2005;23(2):113-20. (Pubitemid 40460651)
17. Evers SM, Ament AJ, Colombo GL, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis. 2007;26(8):531-40. (Pubitemid 47106804)
18. Grzesiowski P, Aguiar-Ibáñez R, Kobryń A, et al. Cost-effectiveness of polysaccharide pneumococcal people aged 65 and above in Poland. Hum Vaccin Immunother. 2012;8(10):1382-94.
19. Silfverdal SA, Berg S, Hemlin C, et al. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine. Vaccine. 2009;27(10):1601-8.
20. Claes C, Reinert RR, von der Schulenburg JM. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur J Health Econ. 2009;10(1):25-38.
21. Giorgi-Rossi P, Merito M, Borgia P. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy. Health Pol. 2009;89(2):225-38.
22. Tilson L, Usher C, Butler K, et al. Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland. Value Health. 2008;11(5):898-903.
23. Lloyd A, Patel N, Scott DA, et al. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Eur J Health Econ. 2008;9(1):7-15.
24. Bergman A, Hjelmgren J, Ortqvist A, et al. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden. Scand J Infect Dis. 2008;40(9):721-9.
25. Hubben GA, Bos JM, Glynn DM, et al. Enhanced decision support for policy makers using a web interface to health-economic models - illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Vaccine. 2007;25(18):3669-78. (Pubitemid 46584758)
26. Rozenbaum MH, van Hoek AJ, Fleming D, et al. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ. 2012;26(345):e6879.
27. Boccalini S, Azzari C, Resti M, et al. Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy. Vaccine. 2011;29(51):9521-8.
28. Boccalini S, Bechini A, Levi M, Tiscione E, Gasparini R, Bonanni P. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Hum Vaccin Immunother. 2013;9(3).
29. Kuhlmann A, Theidel U, Pletz MW, et al. Potential cost-effectiveness and benefit-cost pneumococcal vaccination in Germany. Health Econ Rev. 2012;2(1):4.
30. Rozenbaum MH, Hak E, van der Werf TS, et al. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or = 65 years in the Netherlands. Clin Ther. 2010;32(8):1517-32.
31. Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR. Cost-Effectiveness of a 10- Versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and Sweden. Clin Ther. 2013;35(2):119-34.
32. Van Hoek AJ, Choi YH, Trotter C, et al. The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine. 2012;30(50):7205-13.
33. By A, Sobocki P, Forsgren A, et al. Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model. Clin Ther. 2012;34(1):177-89.
34. Knerer G, Ismaila A, Pearce D. Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise. J Med Econ. 2012;15(1):61-76.
35. Strutton DR, Farkouh RA, Earnshaw SR, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands. J Infect. 2012;64(1):54-67.
36. Díez-Domingo J, Ridao-López M, Gutiérrez-Gimeno MV, et al. Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain). Vaccine. 2011;29(52):9640-8.
37. Rozenbaum MH, Sanders EA, van Hoek AJ, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010;2(340):c2509.
38. Talbird SE, Taylor TN, Knoll S, et al. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine. 2010;19(28 Suppl 6):G23-9.
39. Garattini L, van de Vooren K, Curto A. Pricing human papillomavirus vaccines: lessons from Italy. Pharmacoeconomics. 2012;30(3):213-7.
40. Beutels P. Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination. Vaccine. 2004;22(25-26):3312-22. (Pubitemid 39078747)
41. Garattini L, Koleva D, Casadei G. Modeling in pharmacoeconomic studies: funding sources and outcomes. Int J Technol Assess Health Care. 2010;26(3):330-3.
42. Haute Autorité de Santé. Commission de la Transparence. http://www.has-sante.fr/portail/plugins/ModuleXitiKLEE/types/FileDocument/ doXiti.jsp?id=c-622274. Accessed 18 June 2013.
43. Prevenar: EPAR -Product information. European Medicines Agency. 2008. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/ human/000323/WC500041563.pdf. Accessed 17 June 2013.
44. Synflorix: EPAR-Product information. European Medicines Agency. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/ human/000973/WC500054346.pdf. Accessed 17 June 2013.
45. Prevenar 13: EPAR-Product information. European Medicines Agency. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/ human/001104/WC500057247.pdf. Accessed 17 June 2013.
46. Diagnosedaten der Krankenhäuser nach Behandlungsort ab 2000 (Fälle/Sterbefälle, Pflegetage, durchschnittliche Verweildauer. Gliederungsmerkmale: Jahre, Behandlungsort, Alter, Geschlecht, Verweildauer, ICD10. Statistisches Bundesamt (Hrsg.). 2013. http://www.gbe-bund.de.
47. CapNetz: CAP Moratlitätsdaten. 2009.
48. Ray GT, Whitney CG, Fireman BH, et al. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J. 2006;25(6):494-501. (Pubitemid 43863358)
49. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41.
50. Reinert RR, Haupts S, van der Linden M, et al. Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001-2003. Clin Microbiol Infect. 2005;11(12):985-91. (Pubitemid 41748932)
51. Jansen AG, Rodenburg GD, de Greef SC, et al. Invasive pneumococcal disease in the Netherlands: syndromes, outcome and potential vaccine benefits. Vaccine. 2009;27(17):2394-401.
52. Lepoutre A, Varon E, Georges S et al. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill. 2008;13(35):18962.
53. Rozenbaum MH, Sanders EA, van Hoek AJ et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: An economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010;340:c2509.
54. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the seven serotypes in Prevenar: children aged <2 years in England and Wales by epidemiological year: July-June. Health Protection Agency. 2009. http://www.hpa.org.uk.
55. Sisk JE, Whang W, Butler JC, et al. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: Role of comorbid conditions and race. Ann Intern Med. 2003;138(12):960-8.
56. Ingels H, Rasmussen J, Andersen PH, et al. Danish Pneumococcal Surveillance Collaboration Group 2009-2010. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. Vaccine. 2012;30:3944-50.
57. Statistics Denmark. Data on inpatient pneumonia over age groups in 2011: http://www.dst.dk. Accessed November 29, 2012.
58. Stangerup SE, Tos M. Epidemiology of acute suppurative otitis media. Am J Otolaryngol. 1986;7:47-54. (Pubitemid 16105379)
59. Harboe ZB. Studies on the Epidemiology of Invasive Pneumococcal Disease and Related Mortality in Denmark [doctoral thesis]. Copenhagen, Denmark: University of Copenhagen, Faculty of Health Sciences; 2010.
60. Statistics Denmark. Danish cause of death registry in 2010. http://www.dst.dk. Accessed November 29, 2012.
61. Benfield T, Marlene S, Sørensen HC, et al. Serotype distribution in nonbacteremic pneumococcal pneumonia: implications for pneumococcal conjugate vaccines. Poster presented at: the 8th International Symposium on Pneumococci and Pneumococcal Diseases; March 11-15, 2012; Foz do Iguaçu, Brazil. Poster no. 515.
62. Epidemiologisk årsrapport 2010, Smittskyddsinstitutet Patientregistret, Socialstyrelsen. Stockholm: Elanders Sverige AB; 2011.
63. National Board of Health and Welfare, data on file and http://www.socialstyrelsen.se/Statistik/statistikdatabas.
64. By Å, Sobocki P, Forsgren A, Silferdal SA. Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model. Clin Ther. 2012;34:177-89.
65. Dahl MS, Trollfors B, Claesson BA, et al. Invasive pneumococcal infections in Southwestern Sweden: a second follow-up period of 15 years. Scand J Infect Dis. 2001;33(9):667-72. (Pubitemid 32962857)
66. Choi YH, Jit M, Flasche S, et al. Mathematical modelling longterm effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in the England and Wales. PLoS ONE. 2012;7(7):e39927.
67. van Hoek AJ, Andrews N, Waight PA, et al. Effect of serotype on focus and mortality of invasive pneumococcal disease; coverage of different vaccines and insight into non-vaccine serotypes. PLoS ONE. 2012;7(7):e39150.
68. Trotter C, Petersen I, Sterne J et al. Impact of pneumococcal conjugate vaccination on primary care consultations for otitis media and pneumonia in the UK.
69. Petrou S, Dakin H, Abangma G, et al. Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value Health. 2010;13(5):543-51.
70. Bennett JE, Sumner W 2nd, Downs SM, et al. Parents' utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med. 2000;154(1):43-8. (Pubitemid 30027654)
71. Vold PP, Owens DK. Cost-effectiveness of the pneumococcal vaccine in the United States navy and marine corps. Clin Infect Dis. 2000;30(1):157-64. (Pubitemid 30067074)
72. Engström S, Mölstad S, Nilsson G, et al. Data from electronic patient records are suitable for surveillance of antibiotic prescriptions for respiratory tract infections in primary health care. Scand J Infect Dis. 2004;36(2):139-43. (Pubitemid 38313042)
73. Invasive Haemophilus influenzae in Europe 2006. European Union Invasive Bacterial Infections Surveillance Network. 2007. http://www.hpabioinformatics. org.uk/euibis/documents/2006-hib.pdf.
74. Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR Morb Mortal Wkly Rep. 2008;57(6):144-148 [Errata. MMWR Morb Mortal Wkly Rep 2008;57(09):237].
75. Darenberg J, Henriques NB. The epidemiology of pneumococcal infections - the Swedish experience. Vaccine. 2009;27(Suppl 6):G27-32.
76. Gillian Prior. Chapter 5: Self-reported. In Health Survey for England 1996. 1998. http://www.archive.official-documents.co.uk/document/doh/survey96/ tab5-29.htm. 1998.
77. Oh PI, Maerov P, Pritchard D, et al. A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Clin Ther. 1996;18(1):160-82. (Pubitemid 26268350)
78. Cheng AK, Niparko JK. Cost-utility of the cochlear implant in adults: a meta-analysis. Arch Otolaryngol Head Neck Surg. 1999;125(11):1214-8. (Pubitemid 29526317)
79. Morrow A, De Wals P, Petit G, et al. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol. 2007;18(2):121-7. (Pubitemid 46915304)
80. Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31-32):4203-14. (Pubitemid 39330342)
81. Number of laboratory confirmed invasive pneumococcal disease cases (including meningitis) in England and Wales, 1996-2005. Health Protection Agency. 2010. http://www.hpa.org.uk/webw/HPAweb/HPAweb&HPAwebStandard/ HPAweb-C/1195733751944?p=1203409671918.
82. Johnson AP, Waight P, Andrews N, et al. Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in England. J Infect. 2007;55(5):394-9. (Pubitemid 47611507)
83. Williamson I, Benge S, Mulle M, et al. Consultations for middle ear disease, antibiotic prescribing and risk factors for reattendance: a case-linked cohort study. Br J Gen Pract. 2006;56(524):170-5. (Pubitemid 43355730)
84. Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep. 2005;54(36):893-7.
85. Pneumococcal serotype distribution for samples referred for serotyping epidemiological years (July-June): 2000/1-2005/6. Health Protection Agency. http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/ EpidemiologicalDataPneumococcal/BackgroundEpidemiologyPneumococcal/IPDTables/ pneumoPneumococcalSerotypeDistribution/.
86. Denham BC, Clarke SC. Serotype incidence and antibiotic susceptibility of Streptococcus pneumonia causing invasive disease in Scotland, 1999-2002. J Med Microbiol. 2005;54(Pt 4):327-31. (Pubitemid 40489537)
87. Netherlands Reference Laboratory for Bacterial Meningitis. Bacterial meningitis in the Netherlands. Annual report 2006. Amsterdam: University of Amsterdam; 2007.
88. Rijksinstituut voor Volksgezondheid en Milieu [National Institute for Public Health and the Environment, the Netherlands]. http://www.rivm.nl/.
89. Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760-8.
90. Zhou F, Kyaw MH, Shefer A, et al. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med. 2007;161(12):1162-8. (Pubitemid 350223571)
91. Prosser LA, Ray GT, O'Brien M, et al. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics. 2004;113(2):283-90. (Pubitemid 38177078)
92. Koshy E, Murray J, Bottle A, et al. Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008. Thorax. 2010;65(9):770-4.
93. Maddigan SL, Feeny DH, Johnson JA. Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Qual Life Res. 2005;14(5):1311-20. (Pubitemid 40895753)
94. Oostenbrink R, Moll HA, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol. 2002;55(8):791-9.
95. Diagnostic data of the hospitals (by place of residence): year 2006. Federal Health Monitoring. http://www.gbe-bund.de.
96. Ruckinger S, van der Linden M, Reinert RR, et al. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine. 2009;27(31):4136-41.
97. Dirección General de Salud Pública. Generalitat Valenciana. Conjunto Minimo de Bases de Datos de la Comunidad Valenciana. Valencia. 2010. http://www.sp.san.gva.es.
98. Garcés-Sánchez M, Díez-Domingo J, Álvarez de Labiada T et al. Epidemiología e impacto de la otitis media aguda en la comunidad Valenciana. An Pediatr (Barc). 2004;60(2):125-32.
99. Garcés-Sanchez MD, Díez-Domingo J, Ballester Sanz A et al. Epidemiology of community-acquired pneumonia in children aged less than 5 years old in the Autonomous Community of Valencia (Spain). An Pediatr (Barc). 2005;63(2):125-30. (Pubitemid 41224601)
100. Rodenburg GD, de Greeff SC, Jansen AG, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis. 2010;16(5):816-23.
101. Nelson JC, Jackson M, Yu O, et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine. 2008;26(38):4947-54.
102. von Kries R, Siedler A, Schmitt HJ, et al. Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines. Clin Infect Dis. 2000;31(2):482-7. (Pubitemid 32289580)
103. Kamtsiuris P, Atzpodien K, Ellert U, et al. Prävalenz von somatischen ekrankungen bei kndern und jugendlichen in Deutschland. Ergebnisse des Kinder- und Jugendgesundheitssurveys (KiGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007;50(5-6):686-700.
104. Diagnosedaten der Krankenhäuser 2007. Ad hoc tables for ICD-10 (pneumonia): J09-J18, ICD-10 (AOM): H65-H75 Gesundheitsberichtserstattung des Bundes (GBE). http://www.gbebund.de.
105. Schnabel E, Sausenthaler S, Brockow I, LISA Study Group, et al. Burden of otitis media and pneumonia in children up to 6 years of age: results of the LISA birth cohort. Eur J Pediatr. 2009;168(10):1251-7.
106. Schnoor M, Hedicke J, Dalhoff K, CAPNETZ study group, et al. Approaches to estimate the population-based incidence of community acquired pneumonia. J Infect. 2007;55(3):233-9. (Pubitemid 47248481)
107. Scheifele D, Halperin S, Pelletier L, et al. Invasive pneumococcal infections in Canadian children, 1991-1998: implications for new vaccination strategies. Canadian Paediatric Society/ Laboratory Centre for Disease Control Immunization Monitoring Program, Active (IMPACT). Clin Infect Dis. 2000;31(1):58-64 (Erratum in 2000;31(3):850).
108. Jetté LP, Lamothe F. Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada, from 1984 to 1986: serotype distribution, antimicrobial susceptibility, and clinical characteristics. J Clin Microbiol. 1989;27(1):1-5. (Pubitemid 19021933)
109. Auburtin M, Porcher R, Bruneel F, et al. Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases. Am J Respir Crit Care Med. 2002;165(5):713-7. (Pubitemid 34194763)
110. van de Beek D, de Gans J, Spanjaard L et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 2004;351(18):1849-59. (Erratum in 2005;352(9):950).
111. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol. 1993;137(9):977-88. (Pubitemid 23191065)
112. Kastenbauer S, Pfister HW. Pneumococcal meningitis in adults: Spectrum of complications and prognostic factors in a series of 87 cases. Brain. 2003;126(Pt 5):1015-25. (Pubitemid 36522945)
113. Robert Koch Institute. PneumoWeb data. 2008. http://www.rki.de/cln-048/ nn-371386/DE/Content/Infekt/Sentinel/Pneumoweb/Pneumoweb--node.html?--nnn= true&--nnn=true#doc414778bodyText4.
114. Verschreibungsindex für Pharmazeutika. VIP. Deutschland: IMS Health; 2009.
115. Lauertaxe: Arzneimittelpreise. 2010. https://www.lauer-fischer.de/LF/ Seiten/Verwaltung/Kundencenter.aspx.
116. Institut für das Entgeltsystem im Krankenhaus: DRG Browser 2008-2010. 2010. http://www.g-drg.de.
117. Kassenärztliche Bundesvereinigung: Einheitlicher Bewertungsmaßstab (EBM). http://www.kbv.de.
118. Arbeitsunfähigkeit bei AOK-Pflichtmitgliedern ohne Rentner (Arbeitsunfähigkeitsfälle, Arbeitsunfähigkeitstage, Tage je Fall). Gliederungsmerkmale: Jahre, Deutschland, Geschlecht, ICD-10. Statistisches Bundesamt. http://www.destatis.de.
119. Bevölkerung, Erwerbstätige, Erwerbslose, Erwerbspersonen, Nichterwerbspersonen: Deutschland, Jahre, Altersgruppen. Statistisches Bundesamt (Hrsg.). http://www.destatis.de.
120. Drug costs in the Netherlands (in Dutch). 2009. http://www. medicijnkosten.nl.
121. The Dutch Healthcare Authority. 2009. http://www.nza.nl.
122. British National Formulary. 60th edition. BMJ Group and RPS Publishing. September 2010. http://bnf.org/bnf.
123. NHS reference costs 2008-2009. Department of Health. 2010. http://webarchive.nationalarchives.gov.uk/?/www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-111591.
124. Curtis L. Unit costs of health and social care 2009. Canterbury, UK: Personal Social Services Research Unit (PSSRU), University of Kent; 2009.
125. National Collaborating Centre for Women's and Children's Health. Surgical management of otitis media with effusion in children. Clinical Guideline February 2008. http://www.nice.org.uk/nicemedia/pdf/CG60fullguideline.pdf.
126. Kinane C, Gupta K. Residential care homes for the mentally ill. Implications for a catchment area service. Psych Bull 2001;25:61-6.
127. Curtis L. Unit costs of health and social care 2007. Canterbury, UK: Personal Social Services Research Unit (PSSRU), University of Kent; 2007. http://www.pssru.ac.uk/pdf/uc/uc2007/uc2007.pdf.
128. Department of Health. National tariff 2006/07: payment by results. http://webarchive.nationalarchives.gov.uk/?/www.dh.gov.uk/en/ Managingyourorganisation/Financeandplanning/NHSFinancialReforms/DH-4127039.
129. Bos JM, Rümke H, Welte R, et al. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin Ther. 2003;25(10):2614-30. (Pubitemid 37373936)
130. Plasschaert AI, Rovers MM, Schilder AG, et al. Trends in doctor consultations, antibiotic prescription, and specialist referrals for otitis media in children: 1995e2003. Pediatrics. 2006;117(6): 1879-86. (Pubitemid 46071229)
131. Rote Liste. 2009. http://www.rote-liste.de.
132. Z-index. Taxe (list of drugs registered in the Netherlands). Den Haag, The Netherlands: Z-index; February 2010.
133. Regional Association of Statutory Health Insurance Physicians. 2008.
134. Institute für das Entgelsystem im Krankenhaus gGmbH (InEK). Final report G-DRG 2008. http://www.g-drg.de/cms/index.php/inek-site-de/G-DRG-System- 2008/Abschlussbericht-zur-Weiterentwicklung-des-G-DRG-Systems-und-Report- Browser/Report-Browser-2006-2008.
135. Claes C, Reinert RR, Vauth C et al. Health technology assessment: Heptavalenter Pneumokokkenkonjugat-Impfstoff (PCV7). http://portal.dimdi.de/de/ hta/hta-berichte/hta202-bericht-de.pdf.
136. Rozenbaum MH, Sanders EA, van Hoek AJ, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010;340:c2509.
137. Boletín Oficial del Estado. Ley 16/2008, de 22 de diciembre, de Medidas Fiscales, de Gestión Administrativa y Financiera, y de Organización de la Generalitat. Madrid; 2008. http://www.boe.es/boe/dias/ 2009/01/31/pdfs/BOE-A-2009-1603.pdf.
138. Vespa G, Constenla DO, Pepe C, et al. Estimating the costeffectiveness of pneumococcal conjugate vaccination in Brazil. Rev Panam Salud Publica. 2009;26(6):518-28.
139. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA et al. Guidelines for costing research,methods and standardized prices for economic evaluations in health care. Dutch Health Care Insurance Board, 2004.
140. Lauer-Taxe. 2009. http://www.lauer-fischer.de/LF/.
141. Talbird SE, Taylor TN, Caporale J, et al. Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae-associated disease following vaccination with PCV-7: a multi-country analysis. Vaccine. 2010;28(Suppl. 6):G14-22.